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Abstract
Purpose—Increased follicle-stimulating hormone (FSH) has been associated with lower bone
mineral density (BMD) in animal models and longitudinal studies of women, but a direct effect
has not been demonstrated.
Methods—We tested associations between FSH, non-bone body composition measures and
BMD in 94 younger (aged 50 to 64 years) postmenopausal women without current use of hormone
therapy, adjusting for sex hormone concentrations and clinical risk factors for osteoporosis. Lean
mass, fat mass and areal BMD (aBMD) at the spine, femoral neck and total hip were measured
using dual energy X-ray absorptiometry (DXA). Volumetric BMD (vBMD) was measured at the
distal radius using peripheral quantitative computed tomography (pQCT). Results: FSH was
inversely correlated with lean and fat mass, bioavailable estradiol, spine and hip aBMD, and
vBMD at the ultradistal radius. In the multivariable analysis, FSH was independently associated
with lean mass (β= −0.099, p=0.005) after adjustment for age, race, years since menopause,
bioavailable estradiol, bioavailable testosterone, LH, PTH, SHBG and urine N-telopeptide. FSH
showed no statistically significant association with aBMD at any site or pQCT measures at the
distal radius in adjusted models. Race was independently associated with aBMD, and race and
urine N-telopeptide were independently associated with bone area and vBMD.
Conclusions—After adjustment for hormonal measures and osteoporosis risk factors, higher
concentrations of FSH were independently associated with lower lean mass, but not with BMD.
Previously reported correlations between FSH and BMD might have been due to indirect
associations via lean mass or weight.
© 2011 Elsevier Inc. All rights reserved.
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INTRODUCTION
A 2006 study by Sun et al. suggested that high circulating levels of follicle-stimulating
hormone (FSH) caused hypogonadal bone mineral density (BMD) loss in animal models [1].
Subsequent basic science [2] and clinical [3, 4] studies did not support an independent
association between FSH and BMD, indicating that confounding factors might be
responsible for correlations between FSH and bone mass. The role of non-bone body
composition measures as possible confounders has not been investigated.
In a cross-sectional study of 10 normal-weight and 22 overweight or obese women with
normal menstrual cycles referred to an obesity center for weight loss [5], De Pergola et al.
demonstrated that FSH and luteinizing hormone were inversely associated with BMI
independently of age, insulin levels, estradiol, and inhibin B. The authors interpreted these
findings to mean that body mass may have an inhibitory effect on gonadotropin secretion.
Sowers et al. followed 543 perimenopausal women annually over 6 years (15% of cohort
postmenopausal by sixth study visit) and found increasing FSH concentrations were
associated with increasing fat mass and decreasing lean mass measured by bioelectrical
impedance analysis [6]. Cannon et al. explored possible relationships among FSH, body fat
percentage and BMD in a study of 30 pre- or perimenopausal women aged 20 to 50 [7].
They found that FSH concentrations were correlated with circulating concentrations of bone
resorbing cytokines, and at least one cytokine marker was correlated with body fat
percentage and plasma leptin, but not with BMD. Other investigators have demonstrated that
lean and fat mass are strong independent determinants of BMD in postmenopausal women
[8-12], and fat mass has been hypothesized to play a mediating role in the association of
weight change and sex-hormone binding globulin with total hip BMD in women [8]. Studies
clarifying relationships among FSH, non-bone body composition measures and BMD in
postmenopausal women are lacking.
We previously conducted a cross-sectional study to test the association between serum FSH
and measures of bone strength in 111 postmenopausal women aged 50 to 64 years [4]. In the
multivariable analysis, weight and race were important determinants of BMD, while FSH,
bioavailable estradiol and other hormonal variables did not show statistically significant
associations with hip and spine areal BMD (aBMD) measured by dual-energy X-ray
absorptiometry (DXA) and volumetric BMD (vBMD) measured by peripheral quantitative
computed tomography (pQCT). Because of multicollinearity (strong correlations among
explanatory variables in regression model) among weight, lean mass and fat mass, only
weight could be studied as a correlate of BMD in our original analysis. We now propose to
study relationships among FSH, lean and fat mass and BMD in younger postmenopausal
women without current hormone therapy use. We hypothesize that FSH might be indirectly
associated with BMD via lean mass or fat mass.
METHODS
Study participants
Participants were 94 community-dwelling postmenopausal women aged 50 to 64 years of
mixed ethnic background (self-reported race) and without current hormone use, recruited
between 2005 and 2010 from appointment rosters from primary care clinics at the University
of North Carolina or from the community by university e-mail listservs, posters, and
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referrals by past study participants. Women were eligible for the study if they reported their
last menstrual period to be over 12 months before the study visit. They were excluded if they
were currently using hormone therapy (pills or transdermal), had ever taken an osteoporosis
treatment agent (bisphosphonate, selective estrogen receptor modulator, calcitonin,
teriparatide) or prescribed vitamin D or vitamin D derivative, had a contraindication to DXA
or weighed greater than 305 pounds. Although there were no a priori laboratory criteria, one
participant was excluded after she was found to have a serum estradiol level of 254 with no
history of hormone use. Another enrolled participant could not be included in this analysis
because phlebotomy to obtain her serum sample was unsuccessful. The research protocol
was reviewed and approved by the Institutional Review Board of the University of North
Carolina and the UNC Clinical Translational Research Center. Informed consent was
obtained from all participants at the time of the study visit.
Measurements
Participants were instructed to fast and to urinate no more than once after midnight before
attending a morning study visit in the UNC Clinical Translational Research Center. Serum
and urine collection were completed before 10 AM, and bone imaging was completed while
participants were fasting.
aBMD and non-bone body composition measures—aBMD was measured at the
femoral neck, total femur and spine (L1-L4) in all participants by a trained and certified
radiologic technologist using DXA (Hologic Discovery densitometer, Hologic, Inc.,
Bedford, MA). The technologist was blinded regarding the specific study hypothesis.
Quality control was maintained by daily scanning of an anthropomorphic spine phantom.
The coefficient of variation for the densitometer is 0.6% and the reference limits for
variation are +/− 1.5%. aBMD results were recorded in grams per square centimeter, and as
T scores ([BMD of participant – mean BMD of reference population]/SD of BMD of
reference population) based on Hologic reference norms for white and nonwhite women for
the spine, total hip, femoral neck and distal radius.
Regional and whole body measurements of lean and fat mass were also obtained during the
same DXA scan. A research radiologist (JBR) in the UNC Department of Radiology
reviewed the DXA reports.
Peripheral QCT measures—We measured trabecular vBMD (mg/cm3) at the ultradistal
(4%) radius by pQCT using an XCT2000 scanner (Stratec, Orthometrix). Cortical area and
vBMD were assessed at the 33% distal radius. The scans were analyzed at the distal site
using contour mode 3 with a threshold of 169 to determine the outer edges of the bone, and
peel mode 4 with a threshold of 650 and additional concentric peel of 10% to separate
cortical bone from trabecular bone. For cortical analysis at the diaphyseal sites, we used
bone-separation mode 2, and bone geometry threshold 710 mg/cm3 for area and vBMD.
Based on an analysis of the last 140 phantom scans performed on the XCT2000 sn-91255 at
UNC between January 31, 2007 and January 14, 2010, the precision (average % coefficient
of variation for 4 slices) of the device for pQCT measurements was 0.43% for measures of
trabecular bone density (analysis by Dan Schiferl, Bone Diagnostic Inc., January 22, 2010).
Biochemical analyses—Fasting serum was analyzed for FSH, luteinizing hormone
(LH), estradiol (E2), bioavailable testosterone (bio T), thyroid stimulating hormone (TSH),
parathyroid hormone (PTH), sex-hormone binding globulin (SHBG), bone specific alkaline
phosphatase (BSAP), dehydroepiandrosterone sulfate (DHEAS) and serum 25-
hydroxyvitamin D (25-OHD) as previously described [4]. We used bioavailable (free or
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associated with albumin in the circulation) sex steroid concentrations because they better
reflect the fractions of these factors available to tissues [13]. The bioavailable E2 (bio E2)
concentration was calculated by multiplying the total E2 by the fraction that was non-SHBG
bound as per Khosla et al. [13]. Urine N-telopeptide (NTx) and urine creatinine tests were
processed at Mayo Medical Laboratories.
Other independent variables—Demographic information and risk factors for
osteoporosis and fracture were assessed by trained research assistants. Anthropometric
measurements were taken by a research nurse in the UNC Clinical Translational Research
Center.
Statistical analysis
Descriptive statistics—In the univariate analysis, means and standard deviations were
calculated for demographic and anthropomorphic measures, hormonal variables, weight,
lean and fat mass, and DXA and pQCT measures. Spearman rank correlations, which are not
sensitive to outliers, were used to analyze unadjusted relationships among FSH, bio E2,
other independent variables and the outcomes.
Multivariable analysis with non-bone body composition outcomes—Multiple
linear regression models were constructed using lean mass and fat mass as dependent
variables. Possible covariates included age, race (nonwhite vs. white), years since
menopause, ever use of hormone therapy, FSH, bio E2, bio T, LH, TSH, PTH, SHBG,
BSAP, DHEA-S, serum 25-OHD and urine NTx). Age, race, FSH, bio E2 and bio T were
included as independent variables in both models. To select the remaining independent
variables, we used simple (single variable) linear regression to identify those independent
variables with at least one p value less than 0.05 for unadjusted associations with the lean
and fat mass outcomes, with backward selection to a maximum of 10 variables. Using this
approach, the covariates selected for the lean and fat mass models were age, race, years
since menopause, FSH, bio E2, bio T, LH, PTH, SHBG and urine NTx.
To test for multicollinearity of the explanatory variables in the models, variance inflation
factors were calculated and ranged from 1.22 (years since menopause and PTH) to 3.41
(FSH) [VIF <10 indicates no extreme multicollinearity] for the final model with lean mass
as the outcome, with identical results for the fat mass outcome. Results from the models
were expressed in beta coefficients, which represent the mean change in the dependent
variable for a 1 unit change in the independent variable, adjusted for the other covariates.
For example, a beta coefficient (β) of −0.079 for FSH vs. lean mass would mean for a 1-unit
(1 mIU/ml) increase in FSH, the lean mass was 0.079 kg lower, adjusted for the other
independent variables in the model. Age and years since menopause were divided by 10
before inclusion in the models; after this transformation, a β of −1.559 meant for a 10-year
increase in age, the fat mass was 1.559 kg lower, adjusted for the other independent
variables. Race was coded as 0=nonwhite, 1=white; thus, β<0 for the race variable meant
that bone density was lower in white women compared to nonwhite women.
Multivariable analysis with aBMD and pQCT outcomes—Separate multiple linear
regression models were constructed for these dependent variables: aBMD (g/cm2) at the
spine, femoral neck and total hip; trabecular vBMD (mg/cm3) at the ultradistal radius, total
bone area (mm2), total vBMD, cortical area and cortical vBMD at the 33% distal radius.
The same potential covariates listed for the non-bone models, as well as lean mass and fat
mass, were initially considered. Age, lean mass, fat mass, race, FSH, bio E2 and bio T were
included as independent variables in all aBMD and pQCT models. Using a process similar
to that described for the non-bone models, these other covariates were selected: LH, SHBG
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and urine NTx for the aBMD models; LH and urine NTx for the pQCT models. Variance
inflation factors ranged from 1.21 (age) to 3.71 (FSH) for the final model with femoral neck
aBMD as the outcome, with identical results for spine and hip aBMD. Variance inflation
factors ranged from 1.16 (age) to 3.37 (FSH) for the full model with trabecular vBMD as the
outcome, with very similar results for all of the pQCT outcomes at the 33% distal radius.
Sensitivity analysis: reduced models—Reduced models with the aBMD and pQCT
outcomes were created to confirm FSH was non-significant given only FSH, lean mass and
fat mass included as independent variables. Since the error degrees of freedom is reduced
with each independent variable that is added to a model, the reduced models would
theoretically have slightly greater power to detect associations if they exist.
Statistical analyses were performed using the Stata SE 9.2 software [14]. We used the
Bonferroni correction for adjusting the significance levels for p values to correct for multiple
comparisons [15]. Using this method, p values ≤0.025, ≤0.0167, ≤0.010 were considered
statistically significant for the non-bone (two) outcomes, DXA BMD (three) and pQCT
outcomes (five), respectively. P values greater than these thresholds but less than 0.05 were
considered nearly significant.
Sample size calculations—The planned sample size of 111 women (previously included
16 hormone users) provided 80% power to detect a (population) correlation coefficient
between two continuous-scaled variables as small (in absolute terms) as 0.26 with two-sided
tests of statistical significance at the 0.05 level (e.g., a correlation between FSH and
trabecular vBMD of −0.26). In comparison, an unadjusted r value of 0.44 was found in a
correlation of bioavailable estradiol and trabecular vBMD in a population-based cohort of
women aged 40–59 years [16]. For a correlation of this magnitude, the study provided 99%
power.
RESULTS
Study population and descriptive analysis
Participants had a mean age of 57.5 years, were predominantly white (80%), and were
overweight on average (Table 1). Six women had FSH values below the laboratory cut point
for normal postmenopausal women (range 11.8-19.0, laboratory cut point <21.5). Because
there were no a priori laboratory criteria for study entry and these women otherwise met
inclusion and exclusion criteria, they were included in the analysis. Women in the low-FSH
subgroup were aged 51 to 60, had BMI>29 and total E2 concentrations 3.1 to 28.
Mean FSH was 63.0 mIU/ml with values varying over a wide range (11.8–270 mIU/mL).
FSH was significantly higher in normal weight women compared with overweight and obese
women (mean FSH 89.0 for normal weight vs. 50.2 mIU/ml for women with BMI>=25,
p<0.001). Similarly, bio E2 (0.49 vs. 0.63 ng/dl, p=0.45) and bio T (2.55 vs. 3.35 ng/dl,
p=0.29) were lower in normal weight women compared with heavier women, but these
differences did not reach statistical significance. Mean BMD was in the normal range (T-
score≥–1 at all sites).
Unadjusted Spearman’s correlations
Lean and fat mass (r=0.77, p<0.001) were strongly correlated. FSH (r=−0.70, −0.58, both
p<0.001), LH (r=−0.62, −0.48, both p<0.001) and bio E2 (r=0.42, 0.51, p<0.001) were
moderately correlated with lean and fat mass respectively (Table 2). Age showed no
significant correlation with lean or fat mass while bio T showed a weak correlation with fat
mass (r=0.24, p<0.02).
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Lean mass (r= 0.54 to 0.56, all p<0.001), fat mass (r=0.50 to 0.56, all p<0.001), FSH (r=
−0.40 to −0.42, all p<0.001), bio E2 (r=0.30 to 0.34, all p<0.01) and bio T (r=0.21 to 0.25,
all p<0.05) were significantly correlated with spine, femoral neck and total hip aBMD. Lean
mass showed moderate correlations with total bone area (r=0.45, p<0.001) and cortical area
(r=0.45, p<0.001) at the 33% distal radius. As previously reported [4], FSH, bio E2 and bio
T (all p<0.01) showed significant correlations with trabecular vBMD at the ultradistal
radius.
Multivariable analysis with lean mass and fat mass as outcomes
FSH was independently associated with lean mass (Table 3). Urine NTx had near significant
associations with lean and fat mass. No other significant associations were found.
Multivariable analysis with areal BMD outcomes
Race showed statistically significant associations with femoral neck and total hip aBMD and
a near significant association with spine aBMD (Table 4). Urine NTx had near significant
associations with femoral neck and total hip aBMD.
Multivariable analysis with pQCT outcomes at the 4% (ultradistal) and 33% distal radius
A significant association was found for urine NTx (β=−0.561, p=0.003) and near-significant
associations were found for FSH and LH vs. trabecular vBMD at the ultradistal radius
(Table 5).
At the 33% distal radius, independent associations were found between lean mass (β=0.819,
p=0.008) and race (β=–11.094, p=0.002) vs. total bone area, and urine NTx vs. total bone
vBMD (β=−1.672, p=0.001). Race (β=−8.620, p<0.001) and urine NTx (β=−0.147,
p=0.001) were associated with cortical area and urine NTx (β=−0.544, p=0.001) was
associated with cortical vBMD. Near significant associations were found between lean mass
vs. cortical area and cortical vBMD at the 33% distal radius.
In the reduced models, FSH showed significant associations with aBMD at all sites (all
p<=0.001) when it was the only independent variable. However, FSH showed no significant
association with any aBMD or pQCT measure when FSH and lean mass or FSH and fat
mass were the independent variables.
DISCUSSION
This cross-sectional study of postmenopausal women aged 50 to 64 years recruited from
primary care practices showed FSH was independently associated with lean mass, but not
with DXA and pQCT measures of BMD. These results suggest that prior unadjusted
associations between FSH and BMD were not due to a direct effect of FSH on bone. Instead,
higher FSH concentration was a marker of lower lean mass that was independently
associated with smaller bone area at the 33% distal radius. Although race showed no
significant association with lean or fat mass, it showed independent associations with aBMD
measures and bone area.
Our results are consistent with Drake et al’s interventional study demonstrating that
suppression of FSH secretion did not reduce levels of bone resorption markers in
postmenopausal women [3]. Importantly, they selected a cohort that was clearly past the
menopausal transition, in whom levels of hormonal confounders such as progesterone and
inhibin A and B would be stable and low. Because conflicting data exist regarding whether
associations between FSH and BMD are [17] or are not [1] at least partially estrogen-
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independent, we agree that the separation of pre- and postmenopausal participants is
essential in studies of this type.
We found an independent association for lean mass vs. total bone area, but not lean mass vs.
aBMD or vBMD. This suggests that the effect of lean mass on bone was an increase in bone
size, which might not necessarily be reflected by an increase in aBMD. Also, a past cross-
sectional comparison found that after correcting for fat-free mass, peripheral muscle strength
measures were lower in obese women compared to lean women [18]. In our cohort with a
high proportion of obese participants (36 [38%] with BMI >=30), higher body weight
correlated with higher lean mass, but it is possible that lean mass effects on BMD were more
difficult to detect because of low muscle strength and deconditioning in heavyset women.
Our findings also support that race influences aBMD and cortical area independently, not
only through weight or body composition. The independent associations we found between
urine NTx and total and cortical vBMD are consistent with past studies of urine NTx as a
sensitive biomarker of BMD loss [19, 20].
The lack of an independent association between bio E2, bio T and other hormonal factors vs.
BMD in our analysis suggests hormonal effects are less important than the weight-bearing
effect of increased lean and fat mass on bone. Accordingly, we found independent
associations for weight but not hormonal measures vs. aBMD in an analysis of a similar
cohort [4]. We acknowledge that the predominance of weight-bearing effects over hormonal
factors in our studies might be characteristic of heavier women, since the mean BMI of our
participants was at the lower threshold for obesity.
Our results should be interpreted in light of several limitations. Our study has cross-sectional
design, which can never confirm cause/effect or a mechanistic pathway. In particular,
inconsistent and contradictory research findings occur often in hormonal studies due to
many confounding physiological influences [21]. Confounding can be caused by variables
that are associated with both outcome and exposure and are not on the causal pathway
between exposure and outcome. In our analysis, lean mass may be associated with both FSH
and BMD, but is not an intermediate step in a “causal” pathway.” Controlling for
confounders may decrease bias, but this process can still be problematic due to measurement
error of the confounder included in the model (residual confounding) [22]. Unmeasured
confounding due to omission of a confounder from the model can also be a source of
misleading results. This could be present in our analysis due to the absence of inhibins,
progesterone or other hormonal factors in our models; however, the effects of such factors
are likely to be weak compared to sex hormones, which were included in our multivariable
analysis but did not show independent associations with BMD. Further prospective analysis
would be needed to confirm whether FSH is associated with change in lean mass over time
in postmenopausal women, and whether this relationship influences BMD. Dietary and
physical activity measures would also be important in a prospective study, since these
factors may modify changes in body composition and BMD [23]. Although six women in
the cohort had FSH values below the lab threshold for postmenopausal, their clinical
histories (e.g., four were aged 55 to 60, one had history of bilateral ovariectomy) were
consistent with postmenopausal status, so their low FSH might have been associated with
obesity as has been reported by DePergola [5].
Although our results may help explain previous conflicting findings regarding FSH and
BMD, they are unlikely to change clinical assessment of osteoporosis risk. Weight is a key
predictor of osteoporosis [24-27] and bone loss [28-30] in postmenopausal women, and is
strongly correlated with both lean mass and fat mass (r=0.94 for weight vs. lean mass and
r=0.91 for weight vs. fat mass in our analysis). Weight and age have consistently been found
to be the most important clinical risk factors for osteoporosis in postmenopausal women [24,
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26, 27]. Weight is an easily measured parameter that is routinely assessed in clinics, and can
be used to assess osteoporosis risk in nearly any patient. Our findings support the use of
weight for osteoporosis risk stratification without the need for concurrent measurement of
non-bone body composition or hormonal factors.
In conclusion, FSH was independently associated with lean mass but not BMD measured by
DXA or pQCT. Correlations between FSH and BMD might reflect weight-bearing and non-
weight-bearing effects of greater lean mass and weight on BMD.
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Research highlights for Gourlay et al, “Follicle-stimulating hormone is independently
associated with lean mass but not BMD in younger postmenopausal women”
• Higher FSH levels were independently associated with lower lean mass but not
with BMD.
• Correlations between FSH and BMD might be due to confounding by lean mass
or weight.
• Hormonal effects may be less important than the weight-bearing effect of body
mass on bone.
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Table 1
Subject characteristics (n=94)
Characteristic Mean (SD) or n (%)
Age, y 57.6 (3.6)
Weight, kg
range
80.3 (21.0)
46.8–137.2
BMI (kg/m2)
range
29.9 (7.7)
18.7–49.2
Fat-free lean mass (kg) 45.1 (8.5)
Fat mass (kg) 30.9 (12.7)
Ethnicity/race, n %
 White 67 (70.5)
 Black 24 (25.3)
 Other 4 (4.2)
Years since menopause 11.2 (9.3)
Had a hysterectomy, n % 36 (37.9)
Ever use of hormone therapy, n % 52 (54.7)
Current use of hormone therapy, n % 0
FSH, mIU/ml 63.0 (35.1)range 11.8–270
Bio E2, ng/dl 0.58 (0.83)range 0-6.61
Bio T, ng/dl 3.09 (3.45)
SHBG, nmol/L 41.1 (22.6)
Urine NTx ( nmol bce/mmol urine creatinine) 42.2 (22.8)
Lumbar spine DXA
 aBMD, g/cm2 1.018 (0.137)
 T-score −0.46 (1.17)
 Z-score 0.81 (1.20)
Femoral neck DXA
 aBMD, g/cm2 0.775 (0.138)
 T-score −0.84 (1.05)
 Z-score 0.26 (1.01)
Total hip DXA
 aBMD, g/cm2 0.890 (0.136)
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Characteristic Mean (SD) or n (%)
 T-score −0.57 (0.95)
 Z-score 0.21 (0.93)
4% distal radius, trabecular vBMD (mg/cm3) 199.2 (39.7)
33% distal radius
 Total bone area (mm2) 93.9 (14.6)
 Total vBMD (mg/cm3) 1011.2 (99.0)
 Cortical area (mm2) 74.5 (10.1)
 Cortical vBMD (mg/cm3) 1217.0 (31.4)
aBMD=areal bone mineral density vBMD=volumetric bone mineral density normal values for postmenopausal women: FSH 21.5-131 mIU/ml (see
text re participants with FSH <21.5); total E2 <15 pg/ml; bio E2 not available from reference laboratories; bio T not established; SHBG 20-130
nmol/L
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Table 3
Beta coefficients for independent associations in adjusted models of non-bone body composition measures
(n=94)
Independent variable Beta coefficient (95% CI)
Lean Mass (kg) Fat mass (kg)
Age, y* −2.602 (−6.913, 1.709) −2.009 (−8.994, 4.976)
Race 0.141 (−3.138, 3.420) 1.242 (−4.072, 6.555)
Years since menopause* 1.492 (−.051, 3.034) 1.008 (−1.492, 3.507)
FSH, mIU/ml −0.099 (−0.168, −0.030)‡ −0.105 (−0.216, −0.007)†
Bioavailable estradiol, ng/dl 1.011 (−0.798, 2.820) 2.586 (−0.346, 5.519)
Bioavailable testosterone, ng/dL −0.128 (−0.593, 0.336) −0.410 (−1.162, 0.342)
LH, mIU/ml −0.036 (−0.167, 0.095) −0.042 (−0.038, 0.193)
PTH, pg/ml 0.052 (−0.019, 0.124) 0.078 (−0.038, 0.193)
SHBG, nmol/L −0.042 (−0.125, 0.041) −0.131 (−0.265, 0.003)
Urine NTx ( nmol bce/mmol urine creatinine) −0.075 (−0.146, −0.004)† −0.117 (−0.232, −0.002)†
vBMD volumetric bone mineral density in mg/cm3 CI confidence interval
*
age and years since menopause divided by ten
†
0.025<p<0.05
‡
p<=0.025
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Table 4
Beta coefficients for independent associations in adjusted models of BMD (n=94)
Independent variable Beta coefficient (95% CI)
Spine aBMD Femoral neck aBMD Total hip aBMD
Age, y* 0.029 (−0.040, 0.098) −0.047 (−0.115, 0.021) −0.037 (−0.105, 0.031)
Lean mass, kg 0.005 (−0.0001, 0.009) 0.003 (−0.002, 0.008) 0.001 (−0.003, 0.006)
Fat mass, kg 0.003 (−0.0002, 0.006) 0.002 (−0.001, 0.005) 0 .003 (−0.0003, 0.006)
Race −0.062 (−0.116, −0.007)† −0.106 ( −0.160, −0.052)‡ −0.080 (−0.133, −0.026)‡
FSH, mIU/ml −0.0002 ( −0.001, 0.001) −0.0003 (−0.001, 0 .001) −0.0006 (−0.002, 0.001)
Bio E2, ng/dl 0.011 (−0.042, 0.021) 0.007 (−0.024, 0.039) 0.008 (−0.023, 0.039)
Bio T, ng/dL 0.005 (−0.003, 0.013) −0.003 (−0.010, 0.005) −0.0004 (−0.008, 0.007)
LH, mIU/ml 0.0006 (−0.002, 0.003) 0.001 (−0.001, 0.003) 0.001 (−0.001, 0.003)
SHBG, nmol/L 0.0004 (−0.001, 0.002) −0.0004 (−0.002, 0.001) −0.0006 (−0.002, 0.0008)
Urine NTx ( nmol bce/
mmol urine creatinine)
−0.001 (−0.002, 0.00005) −0.001 (−0.003, −0.0001)† −0.001 (−0.003, −0.0001)†
aBMD areal bone mineral density in g/cm2 CI confidence interval
*
age divided by ten
†
0.0167<p<0.05
‡
p<=0.0167
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